Compounds for treatment of fluoroquinolone-resistant bacteria

Joseph S Bair; Paul J Hergenrother; Elizabeth I Parkinson

Compounds for treatment of fluoroquinolone-resistant bacteria

Joseph S Bair (Inventor), Paul J Hergenrother (Inventor), Elizabeth I Parkinson (Inventor)

Research output: Patent

Abstract

Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.

Original language	English (US)
U.S. patent number	9920069
State	Published - Mar 20 2018

Library availability

Discover UIUC Full Text

Cite this

@misc{276e67339b814814a7dc80e143a18d8f,

title = "Compounds for treatment of fluoroquinolone-resistant bacteria",

abstract = "Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.",

author = "Bair, {Joseph S} and Hergenrother, {Paul J} and Parkinson, {Elizabeth I}",

note = "GOVERNMENT SUPPORT This invention was made with government support under Grant No. R01HL090699 awarded by the National Institutes of Health. The government has certain rights in the invention.; 9920069",

year = "2018",

month = mar,

day = "20",

language = "English (US)",

type = "Patent",

}

TY - PAT

T1 - Compounds for treatment of fluoroquinolone-resistant bacteria

AU - Bair, Joseph S

AU - Hergenrother, Paul J

AU - Parkinson, Elizabeth I

N1 - GOVERNMENT SUPPORT This invention was made with government support under Grant No. R01HL090699 awarded by the National Institutes of Health. The government has certain rights in the invention.

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.

AB - Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.

M3 - Patent

M1 - 9920069

ER -

Compounds for treatment of fluoroquinolone-resistant bacteria

Abstract

Library availability

Fingerprint

Cite this